KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Net Cash Flow data on record, last reported at $65.8 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 66.6% year-over-year to $65.8 million; the TTM value through Dec 2025 reached -$1.0 billion, down 213.13%, while the annual FY2025 figure was -$1.0 billion, 213.13% down from the prior year.
  • Net Cash Flow reached $65.8 million in Q4 2025 per JAZZ's latest filing, down from $136.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.0 billion in Q1 2021 and bottomed at -$1.2 billion in Q2 2021.
  • Average Net Cash Flow over 5 years is $16.9 million, with a median of $60.1 million recorded in 2023.
  • The widest YoY moves for Net Cash Flow: up 1495.57% in 2021, down 1538.39% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$78.9 million in 2021, then soared by 147.11% to $37.2 million in 2022, then soared by 353.98% to $168.8 million in 2023, then grew by 16.7% to $197.0 million in 2024, then crashed by 66.6% to $65.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $65.8 million in Q4 2025, $136.0 million in Q3 2025, and -$676.7 million in Q2 2025.